CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.

Joel W Neal Nick PavlakisSang-We KimYasushi GotoSun Min LimGiannis S Mountzios Elena FountzilasAnastasia MochalovaDaniel C Christoph Alessandra Bearz Xavier Quantin Ramon PalmeroVladan AnticElaine ChunTirupathi Rao EdubilliYa-Chen LinMahrukh HuseniMarcus BallingerVilma GraupnerDominic CurranPiet VervaetThomas Newsom-Davis

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Atezolizumab plus cabozantinib after disease progression following anti-PD-L1/PD-1 immunotherapy and platinum-containing chemotherapy for metastatic NSCLC did not improve OS compared with docetaxel. Safety was consistent with known profiles of these agents.

Keyphrases

phase iii
locally advanced
squamous cell carcinoma
small cell lung cancer
open label
clinical trial
rectal cancer
phase ii
double blind
dna damage
placebo controlled
radiation therapy
metastatic renal cell carcinoma
randomized controlled trial
study protocol
chemotherapy induced
oxidative stress